GLENMARK PHARMACEUTICALS
|
|
| BOM : 532296 NSE : GLENMARK | |
| LT :
Long Term Analysis
Fundamentals : Average
Valuation : Bad [Stock is Expensive] Debt : Average |
Updated: |
| ST :
Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Upward Pledged Shares : None or < 25% |
Jun 23,2025 |
|
Price(EOD): ₹ 1,686.10
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
| MCap: ₹ 47,581.74 Cr | |
| Industry Peers & Returns | 1W | 1M | 1Y |
| GLENMARK PHARMACEUTICALS | 2% | 18.9% | 32.4% |
| SUN PHARMACEUTICAL INDUSTRIES | 0.8% | -1.3% | 10.6% |
| DIVIS LABORATORIES | 1.5% | 2.3% | 47.2% |
| CIPLA | -0.3% | 0.9% | -3.8% |
| TORRENT PHARMACEUTICALS | -2.7% | -0.3% | 9.9% |
| DR REDDYS LABORATORIES | -0.1% | 7.2% | 11.3% |
| MANKIND PHARMA | -2.3% | -5.5% | 3.4% |
| ZYDUS LIFESCIENCES | -0.6% | 5% | -10.9% |
| LUPIN | -0.8% | -2.6% | 23.8% |
FUNDAMENTAL ANALYSIS OF GLENMARK PHARMACEUTICALS
[ Q(TTM): Mar2025, Y: Mar2024
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF GLENMARK PHARMACEUTICALS
[As on : Jun 23,2025
]
| Ratio | Consolidated | |
|---|---|---|
|
P/E P/B P/S |
45.44
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 1,047.14 Cr
[Latest Qtr - Mar2025 - Consolidated Results ] 5.38
P/B Calculated based on Book Value of Rs 8,849.44 Cr
[Latest Year - Mar2025 - Consolidated Results ] 3.57
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 13,321.70 Cr
[Latest Qtr - Mar2025 - Consolidated Results ] |
|
| Financial Ratios → | ||
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
174% 43% 74% |
SHARE PRICE MOMENTUM OF GLENMARK PHARMACEUTICALS
GLENMARK PHARMACEUTICALS vs SENSEX
DEBT OF GLENMARK PHARMACEUTICALS
| Year | Debt/Equity ratio | |
|---|---|---|
| Standalone | Consolidated | |
|
2024 2023 2022 Avg_3yrs |
0.03 0.18 0.22 0.14 |
0.13 0.46 0.4 0.33 |
|
[Last Annual Data : Mar2024]
|
||
| Financial Ratios → | ||
PLEDGED PROMOTER SHARES OF GLENMARK PHARMACEUTICALS
| Pledged Promoter Shares |
0 % | |
|---|---|---|
| As on : Mar2025 | ||
If less than 25% | Good |
|
| If between 25% and 50% | Neutral | |
| If greater than 50% | Bad | |
| Shareholding Pattern → | ||
QTRLY RESULTS OF GLENMARK PHARMACEUTICALS
| Consolidated | Q-o-Q | Y-o-Y |
|---|---|---|
|
Revenue Op Profit Profit Before Tax Profit After Tax |
-3.88% -6.53% -98.25% -98.74% |
6.31% 11.24% -98.5% 100.35% |
| QtrlyTrend |
-2 | |
| Latest Qtr: Mar2025 | ||
| Quarterly Result Analysis → | ||
GLENMARK PHARMACEUTICALS related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% |
| BSE MIDSMALLCAP | 4.7% | 9% | 8.4% |
| BSE LARGEMIDCAP | 4.5% | 7.2% | 8.3% |
| BSE 500 SHARIAH | 4.3% | 4.3% | 1.1% |
| BSE MOMENTUM INDEX | 1% | 4.1% | -3.2% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY ALPHA 50 | 0.9% | 5.9% | -6.9% |
| NIFTY200 ALPHA 30 | 0.8% | 5.7% | -8.9% |
| NIFTY500 MOMENTUM 50 | 0.5% | 5.3% | -12% |
| NIFTY MIDSMALLCAP400 MOMENTUM QUALITY 100 INDEX | -0.2% | 3.6% | -3.9% |
| NIFTY 200 | -0.2% | 1.6% | 3.7% |
You may also like the below Video Courses
FAQ about GLENMARK PHARMACEUTICALS
Is GLENMARK PHARMACEUTICALS good for long term investment?
As on Jun 23,2025, the Fundamentals of GLENMARK PHARMACEUTICALS look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of GLENMARK PHARMACEUTICALS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is GLENMARK PHARMACEUTICALS UnderValued or OverValued?
As on Jun 23,2025, GLENMARK PHARMACEUTICALS is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of GLENMARK PHARMACEUTICALS ?
As on Jun 23,2025, the Intrinsic Value of GLENMARK PHARMACEUTICALS is Rs. 970.57 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 615.31
Fair Value [Median EV / Sales Model] : Rs. 1,180.92
Fair Value [Median Price / Sales Model] : Rs. 970.57
Estimated Median Fair Value of GLENMARK PHARMACEUTICALS : Rs. 970.57
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.
